IHD, AIMA to develop at-home endometriosis test

LabPulse.com staff writers
Aug 23, 2022
2022 08 24 19 47 7252 Endometriosis 400

Innovative Health Diagnostics (IHD) has partnered with Aima Laboratories to develop an at-home test that detects endometriosis.

The test identifies microRNA biomarkers that are differentially expressed in women with endometriosis compared to women without the disease.

The test will complement laparoscopic procedures with the goal of eliminating diagnostic delays and allowing patients to be treated sooner.

Latest in Point-of-Care Testing
Blood collection on the Babson Diagnostics hand-warmer.
Babson adds hand-warming to blood testing mini-draws in Texas pharmacies
April 16, 2024
Brain Abstract Social
FDA clears another blood-based TBI POC test
April 1, 2024
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Omb Final Rule Laboratory Developed Tests March124
FDA LDT oversight battle: Are we close?
March 6, 2024
Related Stories
Endometriosis Social
Artificial Intelligence
NIH’s systematic review finds AI may improve detection of underdiagnosed condition
Ai Woman Social
Artificial Intelligence
AI system in development aims for earlier endometriosis diagnosis
2020 05 15 22 29 3148 Test Tube Liquid Sample 400
Women's Health
Innovative Health launches B2B platform for at-home testing
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Point-of-Care Testing
Babson adds hand-warming to blood testing mini-draws in Texas pharmacies
By LabPulse.com staff writers
Austin, TX-based Babson Diagnostics said it has received positive feedback for its hand-warmer, which is used as part of a finger-stick blood sample collection device in retail pharmacies.
April 16, 2024
Blood collection on the Babson Diagnostics hand-warmer.
FDA clears another blood-based TBI POC test
By LabPulse.com staff writers
Abbott furthers its point-of-care (POC) assay for measuring traumatic brain injury biomarkers from whole blood.
April 1, 2024
Brain Abstract Social
Labcorp acquires BioReference Health assets
By LabPulse.com staff writers
Labcorp and Opko Health subsidiary BioReference Health have announced that they have made an agreement for Labcorp to acquire certain of BioReference Health’s assets.
March 28, 2024
Hands Shaking2 Social
FDA LDT oversight battle: Are we close?
By Liz Carey
New directions in laboratory developed test (LDT) regulation appeared closer to final rule-making with the March 1 Office of Management and Budget (OMB) acceptance of the LDT final rule, pending regulatory review: a flurry of final rule-making thoughts.
March 6, 2024
Omb Final Rule Laboratory Developed Tests March124
Quest Diagnostics seeks to get a jump on PFAS testing in communities
By Liz Carey
Researchers often use people’s blood PFAS levels as a proxy for exposure to perfluoroalkyl and polyfluoroalkyl substances, the "forever chemicals" found in certain products and the environment.
February 13, 2024
This U.S. Geological Survey (USGS) map shows the number of PFAS detected in tap water samples from select sites across the nation. The findings are based on a USGS study of samples taken between 2016 and 2021 from private and public supplies at 716 locations. The map does not represent the only locations in the U.S. with PFAS. (Source: USGS, public domain.)
Roche signs $350M deal to buy POC technology from LumiraDx
By LabPulse.com staff writers
Roche has entered into a definitive agreement to purchase point-of care (POC) technologies from LumiraDx for $295 million, with an additional payment of up to $55 million to fund the POC diagnostics platform business until the transaction closes.
January 3, 2024
Hands Shaking Deal Social
Quest Diagnostics launches test panel for novel psychoactive substances
By LabPulse.com staff writers
The new "confirmatory testing service" will use definitive liquid chromatography with advanced tandem mass spectrometry-based testing to establish NPS misuse.
December 19, 2023
Quest Diagnostics Newsroom Media Gallery Photo Social
FDA plans to increase oversight of LDTs garner strong response
By Nick Paul Taylor
Plans to increase U.S. Food and Drug Administration (FDA) oversight of laboratory-developed tests (LDTs) have drawn a strong response from trade groups, individuals, and organizations.
November 17, 2023
Fda Sign Dc Social
Talis Biomedical to lay off 90% of workforce, pursue strategic alternatives
By LabPulse.com staff writers
POC testing company Talis Biomedical has announced that it will lay off 90% of its employees and has begun exploring strategic alternatives.
November 15, 2023
Layoff Woman Belongins
Polygenic risk score tests don’t meet expectations, U.K. study shows
By Matt Limb
Polygenic risk scores “perform poorly in screening and prediction of common disease,” failing to identify nearly 90% of patients who develop disease, according to a U.K. study.
October 26, 2023
Dna Sequencing Genome Social
U.K. researchers recommend routine diabetes screening in EDs
By Matt Limb
Diabetes screening should be introduced for patients attending hospital emergency departments (EDs) to prompt earlier treatment where necessary and reduce major health risks, say researchers.
October 10, 2023
Lab Hb A1c Diabetes Social
U.S. government investing $600M in COVID-19 test manufacturing
By LabPulse.com staff writers
The U.S. Department of Health and Human Services announced that it is investing $600 million in funding into COVID-19 test manufacturing.
September 26, 2023
Dollar Money Coronavirus Mask Social
Page 1 of 41
Next Page